ENVERIC BIOSCIENCES, INC.: nonoperating income or expense
Nonoperating income or expense for ENVERIC BIOSCIENCES, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All ENVERIC BIOSCIENCES, INC. financial histories
What this measure means
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
Exact concept: us-gaap:NonoperatingIncomeExpense. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2015-01-01 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 2,461 | USD | 2026-03-27 | 10-K · 0001493152-26-013294 |
| 2024-01-01 | 2024-12-31 | 66,209 | USD | 2026-03-27 | 10-K · 0001493152-26-013294 |
| 2023-01-01 | 2023-12-31 | -814,379 | USD | 2025-03-28 | 10-K · 0001641172-25-001296 |
| 2022-01-01 | 2022-12-31 | 7,457,713 | USD | 2024-03-26 | 10-K · 0001493152-24-011210 |
| 2021-01-01 | 2021-12-31 | 8,191,719 | USD | 2023-06-09 | 10-K/A · 0001493152-23-020625 |
| 2020-01-01 | 2020-12-31 | -1,247,359 | USD | 2022-03-31 | 10-K · 0001493152-22-008510 |
| 2019-01-01 | 2019-12-31 | 114,139 | USD | 2021-04-01 | 10-K · 0001493152-21-007757 |
| 2018-01-01 | 2018-12-31 | -3,402,554 | USD | 2020-03-25 | 10-K · 0001140361-20-006825 |
| 2017-01-01 | 2017-12-31 | -570,044 | USD | 2019-03-26 | 10-K · 0001140361-19-005573 |
| 2016-01-01 | 2016-12-31 | -1,145,287 | USD | 2018-04-02 | 10-K · 0001140361-18-016275 |
| 2015-01-01 | 2015-12-31 | -148,553 | USD | 2017-04-04 | 10-K/A · 0001079974-17-000131 |
Related financial histories
- ENVERIC BIOSCIENCES, INC.: total assets
- ENVERIC BIOSCIENCES, INC.: total liabilities
- ENVERIC BIOSCIENCES, INC.: stockholders equity
- ENVERIC BIOSCIENCES, INC.: cash and cash equivalents
- ENVERIC BIOSCIENCES, INC.: net income or loss
- ENVERIC BIOSCIENCES, INC.: operating cash flow
- ENVERIC BIOSCIENCES, INC.: capital expenditure payments
- ENVERIC BIOSCIENCES, INC.: revenue
- ENVERIC BIOSCIENCES, INC.: financing cash flow
- ENVERIC BIOSCIENCES, INC.: investing cash flow
- ENVERIC BIOSCIENCES, INC.: retained earnings or deficit
- ENVERIC BIOSCIENCES, INC.: basic weighted-average shares
- ENVERIC BIOSCIENCES, INC.: diluted weighted-average shares
- ENVERIC BIOSCIENCES, INC.: basic earnings per share
- ENVERIC BIOSCIENCES, INC.: diluted earnings per share
- ENVERIC BIOSCIENCES, INC.: income tax expense or benefit
- ENVERIC BIOSCIENCES, INC.: net property, plant and equipment
- ENVERIC BIOSCIENCES, INC.: share-based compensation expense
- ENVERIC BIOSCIENCES, INC.: operating income or loss
- ENVERIC BIOSCIENCES, INC.: current assets
- ENVERIC BIOSCIENCES, INC.: interest expense
- ENVERIC BIOSCIENCES, INC.: current liabilities
- ENVERIC BIOSCIENCES, INC.: current accounts payable
- ENVERIC BIOSCIENCES, INC.: goodwill carrying amount
- ENVERIC BIOSCIENCES, INC.: net finite-lived intangible assets
- ENVERIC BIOSCIENCES, INC.: net current accounts receivable
- ENVERIC BIOSCIENCES, INC.: operating expenses
- ENVERIC BIOSCIENCES, INC.: gross profit
- ENVERIC BIOSCIENCES, INC.: cost of revenue
- ENVERIC BIOSCIENCES, INC.: selling, general and administrative expense
- ENVERIC BIOSCIENCES, INC.: research and development expense
- ENVERIC BIOSCIENCES, INC.: common shares outstanding
- ENVERIC BIOSCIENCES, INC.: cash including restricted cash
- ENVERIC BIOSCIENCES, INC.: additional paid-in capital
- ENVERIC BIOSCIENCES, INC.: accumulated other comprehensive income or loss
- ENVERIC BIOSCIENCES, INC.: total equity including noncontrolling interests
- ENVERIC BIOSCIENCES, INC.: operating lease right-of-use asset
- ENVERIC BIOSCIENCES, INC.: operating lease liability
- ENVERIC BIOSCIENCES, INC.: long-term debt
- ENVERIC BIOSCIENCES, INC.: accumulated depreciation on property, plant and equipment
- ENVERIC BIOSCIENCES, INC.: net intangible assets excluding goodwill
- ENVERIC BIOSCIENCES, INC.: accrued current liabilities
- ENVERIC BIOSCIENCES, INC.: prepaid expenses and other current assets
- ENVERIC BIOSCIENCES, INC.: pre-tax income or loss from continuing operations
- ENVERIC BIOSCIENCES, INC.: profit or loss including noncontrolling interests
- ENVERIC BIOSCIENCES, INC.: comprehensive income or loss
- ENVERIC BIOSCIENCES, INC.: net income available to common stockholders
- ENVERIC BIOSCIENCES, INC.: general and administrative expense
- ENVERIC BIOSCIENCES, INC.: depreciation expense
- ENVERIC BIOSCIENCES, INC.: amortization of intangible assets
- ENVERIC BIOSCIENCES, INC.: current income tax expense or benefit
- ENVERIC BIOSCIENCES, INC.: deferred income tax expense or benefit
- ENVERIC BIOSCIENCES, INC.: interest paid, net
- ENVERIC BIOSCIENCES, INC.: proceeds from issuing common stock
- ENVERIC BIOSCIENCES, INC.: change in accounts receivable
Inspect the source
- Entity
- ENVERIC BIOSCIENCES, INC. / CIK 0000890821
- Captured
- 2026-09-20T05:03:46.618Z
- SEC response SHA-256
ed23dbf99f9ce404ef7949b5b1b4b3a643f25caca94a6c8cd8444309157de101
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0000890821.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))